Psoriatic arthritis

Showing results 1 - 10 of 38

Sorted by most recent

TitleAuthorDate

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study

Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibáñez, Tatiana V Korotaeva, Frederic Lavie, Wim Noël, Michael T Nurmohamed, Petros P Sfikakis, Mohamed Sharaf, Elke Theander, Josef S Smolen

25 January 2023

Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin

Alba Boix-Amorós, Michelle H Badri, Julia Manasson, Rebecca B Blank, Rebecca H Haberman, Andrea L Neimann, Parvathy V Girija, Anthony Jimenez Hernandez, Adriana Heguy, Sergei B Koralov, Richard Bonneau, Jose C Clemente, Jose U Scher

19 January 2023

Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease

Liliana F Mellor, Nuria Gago-Lopez, Latifa Bakiri, Felix N Schmidt, Björn Busse, Simon Rauber, Maria Jimenez, Diego Megías, Sergio Oterino-Sogo, Ricardo Sanchez-Prieto, Sergei Grivennikov, Xinzhu Pu, Julia Oxford, Andreas Ramming, Georg SchettSee the full list of authors

12 September 2022

Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial

Celia AJ Michielsens, Nathan den Broeder, Frank HJ van den Hoogen, Elien AM Mahler, Steven Teerenstra, Désirée van der Heijde, Lise M Verhoef, Alfons A den Broeder

12 September 2022

Concise report: a minimal-invasive method to retrieve and identify entheseal tissue from psoriatic arthritis patients

Milena L Pachowsky, Maria Gabriella Raimondo, Cong Xu, Simon Rauber, Koray Tascilar, Hannah Labinsky, Mario Vogg, Mina Saad Aziz Saad, David Simon, Juergen Rech, Alina Soare, Lars Braeuer, Arnd Kleyer, Georg Schett, Andreas Ramming

12 July 2022

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure

Atul A Deodhar, Bernard Combe, Ana P Accioly, Rebecca Bolce, Danting Zhu, Amanda M Gellett, Aubrey Trevelin Sprabery, Gerd-Rüdiger R Burmester

10 June 2022

Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis

Philip J Mease, Atul A Deodhar, Désirée van der Heijde, Frank Behrens, Alan J Kivitz, Jeffrey Neal, Jonghyeon Kim, Shalabh Singhal, Miroslawa Nowak, Subhashis Banerjee

16 May 2022

Persistence and effectiveness of the IL-12/23 pathway inhibitor ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: 1-year results from the real-world PsABio Study

Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatríz Joven-Ibáñez, Tatiana V Korotaeva, Frederic Lavie, Wim Noël, Michael T Nurmohamed, Petros P Sfikakis, Elke Theander, Josef S Smolen

16 May 2022

Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis

Sayam Dubash, Oras A Alabas, Xabier Michelena, Leticia Garcia-Montoya, Richard J Wakefield, Philip S Helliwell, Paul Emery, Dennis G McGonagle, Ai Lyn Tan, Helena Marzo-Ortega

10 March 2022

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial

Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Gabriela Alperovich, Wenjing Lu, Zailong Wang, Ahmed M Soliman, Ann Eldred, Lisa Barcomb, Alan Kivitz

14 February 2022

12 3 4 Next